Stent Manufacturing in European Union 2026: Industry Statistics & Trends

The stent manufacturing industry in the European Union is a specialized segment of the broader medical technology sector, focused on the production of high-risk Class III cardiovascular and non-vascular implantable devices. Driven by an aging population and increasing prevalence of chronic cardiovascular conditions, the regional market for stents reached approximately $3.3 billion in 2023 (industry sources, 2024). The industry is currently navigating a complex transition toward stricter clinical evidence requirements under the EU Medical Device Regulation (MDR 2017/745), which has increased operational costs for manufacturers while fostering high barriers to entry.

Industry snapshot

Key public data points

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Stent Manufacturing in European Union industry cover?

Stent manufacturing involves the precision engineering and fabrication of expandable scaffolds used to maintain patency in tubular structures within the body. These devices are primarily classified as Class III medical devices under EU regulations due to their high-risk, long-term invasive nature.

• •Primary categories include vascular stents (coronary, peripheral, neurovascular) and non-vascular stents (gastrointestinal, urological, pulmonary).
• •Manufacturing processes require cleanroom environments and specialized material science expertise, such as cobalt-chromium alloys or bioresorbable polymers.
• •Regulated under Regulation (EU) 2017/745, requiring rigorous clinical evaluation and technical documentation for CE marking.

Who operates in the industry and how is it structured?

The EU stent landscape is characterized by a mix of large multinational corporations with extensive R&D footprints and agile, specialized European firms. While production is globalized, key manufacturing clusters exist in countries like Ireland, Germany, and France, supported by robust medtech ecosystems.

• •Major global players dominate market share, but independent EU-based manufacturers maintain niches in specialized bioactive and drug-eluting stent (DES) technologies.
• •The broader European medical technology sector employs over 930,000 people across 2 million products (MedTech Europe, 2025).
• •Sub-contracted manufacturing accounts for approximately 2.4% of total EU production value (Eurostat, 2024).

What drives demand in the industry?

Demand is fundamentally anchored by demographic shifts and the rising global burden of cardiovascular diseases, which remain the leading cause of death. Healthcare system resilience and the push for minimally invasive surgical techniques further incentivize the adoption of advanced stent technologies.

• •Aging demographics in Europe increase the patient pool for percutaneous coronary intervention (PCI) procedures.
• •Advancements in interventional cardiology and the rise of hybrid operating rooms drive demand for more sophisticated, lesion-specific stents.
• •Healthcare digitalization and improved diagnostic screening lead to earlier identification of arterial stenoses.

Who are the notable companies in the industry?

Competition is intense, driven by continuous innovation in stent coating technologies and delivery systems. While US-based multinationals maintain a significant presence in the EU, several European entities remain critical to regional supply chains and specialized clinical applications.

• •Notable companies active in the EU include: Medtronic PLC (Ireland/USA), Boston Scientific Corp (Ireland/USA), B. Braun Melsungen AG (Germany), BIOTRONIK SE & Co. KG (Germany), and Hexacath (France).
• •Competition is characterized by high R&D intensity and the necessity of long-term clinical trial data to secure market access.
• •Market rivalry is increasingly focused on reducing restenosis rates through bioactive and drug-eluting stent innovations.

How is the industry regulated?

The industry operates under the strict oversight of the EU Medical Device Regulation (MDR), which replaced older directives to enhance patient safety and product traceability. Compliance is a major operational hurdle, requiring manufacturers to engage with Notified Bodies for extensive conformity assessments.

• •Regulation (EU) 2017/745 mandates rigorous clinical investigations for all Class III devices, including existing stents.
• •Manufacturers must maintain an active Quality Management System (QMS) certified to ISO 13485 standards.
• •The European Medicines Agency (EMA) provides expert panels to advise on high-risk medical devices, including breakthrough technologies.

Government, statistical and trade sources used for this Claight analysis.

• Eurostat Industrial Production Statistics 2024 ·
• MedTech Europe: The European Medical Technology in Figures 2025 ·
• European Medicines Agency (EMA) Medical Devices Regulatory Overview 2025 ·
• industry sources: Europe Stents Market Size & Outlook 2023-2030 ·
• Regulation (EU) 2017/745 (Medical Device Regulation)